Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Research & Development (2016 - 2026)

Cytosorbents filings provide 14 years of Research & Development readings, the most recent being -$640040.0 for Q4 2024.

  • On a quarterly basis, Research & Development fell 115.62% to -$640040.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $5.0 million, a 68.34% decrease, with the full-year FY2025 number at $3.4 million, down 32.18% from a year prior.
  • Research & Development hit -$640040.0 in Q4 2024 for Cytosorbents, down from $1.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.1 million in Q4 2021 to a low of -$640040.0 in Q4 2024.
  • Median Research & Development over the past 5 years was $3.3 million (2022), compared with a mean of $3.1 million.
  • Biggest five-year swings in Research & Development: skyrocketed 143.07% in 2021 and later plummeted 115.62% in 2024.
  • Cytosorbents' Research & Development stood at $2.7 million in 2020, then surged by 128.51% to $6.1 million in 2021, then tumbled by 44.57% to $3.4 million in 2022, then increased by 20.42% to $4.1 million in 2023, then plummeted by 115.62% to -$640040.0 in 2024.
  • The last three reported values for Research & Development were -$640040.0 (Q4 2024), $1.9 million (Q3 2024), and $1.5 million (Q2 2024) per Business Quant data.